Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism A1298C (Glu429Ala) Predicts Decline in Renal Function over Time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC)

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2011 May 27

PMID 21613384

Citations 12

Authors

Maple M Fung

Rany M Salem

Michael S Lipkowitz

Vibha Bhatnagar

Braj Pandey

Nicholas J Schork

Daniel T OConnor

Affiliations

Soon will be listed here.

Abstract

Background: Hyperhomocysteinemia is associated with increased venous thrombosis and cardiovascular disease (CVD). Mutations in the human methylenetetrahydrofolate reductase (MTHFR) gene have been associated with increased homocysteine levels and risks of CVD in various populations including those with kidney disease. Here, we evaluated the influence of MTHFR variants on progressive loss of kidney function.

Methods: We analyzed 821 subjects with hypertensive nephrosclerosis from the longitudinal National Institute of Diabetes and Digestive and Kidney Diseases African-American Study of Kidney Disease and Hypertension (AASK) Trial to determine whether decline in glomerular filtration rate (GFR) over ∼4.2 years was predicted by common genetic variation within MTHFR at non-synonymous positions C677T (Ala222Val) and A1298C (Glu429Ala) or by MTHFR haplotypes. The effect on GFR decline was then supported by a study of 1333 subjects from the San Diego Veterans Affairs Hypertension Cohort (VAHC), followed over ∼4.5 years. Linear effect models were utilized to determine both genotype [single-nucleotide polymorphism (SNP)] and genotype (SNP)-by-time interactions.

Results: In AASK, the polymorphism at A1298C predicted the rate of GFR decline: A1298/A1298 major allele homozygosity resulted in a less pronounced decline of GFR, with a significant SNP-by-time interaction. An independent follow-up study in the San Diego VAHC subjects supports that A1298/A1298 homozygotes have the greatest estimated GFR throughout the study. Haplotype analysis with C677T yielded concurring results.

Conclusion: We conclude that the MTHFR-coding polymorphism at A1298C is associated with renal decline in African-Americans with hypertensive nephrosclerosis and is supported by a veteran cohort with a primary care diagnosis of hypertension. Further investigation is needed to confirm such findings and to determine what molecular mechanism may contribute to this association.

Citing Articles

Vitamin B12 deficiency in dialysis patients: risk factors, diagnosis, complications, and treatment: A comprehensive review.

Araji G, Keesari P, Chowdhry V, Valsechi-Diaz J, Afif S, Diab W World J Nephrol. 2024; 13(4):100268.

PMID: 39723360 PMC: 11572648. DOI: 10.5527/wjn.v13.i4.100268.

Towards Precision Medicine for Hypertension: A Review of Genomic, Epigenomic, and Microbiomic Effects on Blood Pressure in Experimental Rat Models and Humans.

Padmanabhan S, Joe B Physiol Rev. 2017; 97(4):1469-1528.

PMID: 28931564 PMC: 6347103. DOI: 10.1152/physrev.00035.2016.

Relationship of MTHFR gene polymorphisms with renal and cardiac disease.

Trovato F, Catalano D, Ragusa A, Martines G, Pirri C, Buccheri M World J Nephrol. 2015; 4(1):127-37.

PMID: 25664255 PMC: 4317623. DOI: 10.5527/wjn.v4.i1.127.

Signaling pathway genes for blood pressure, folate and cholesterol levels among hypertensives: an epistasis analysis.

Wei L, Menon S, Griffiths L, Gan S J Hum Hypertens. 2014; 29(2):99-104.

PMID: 25055800 DOI: 10.1038/jhh.2014.53.

Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis.

Gao X, Zhang G, Wang Y, Zhang H PLoS One. 2014; 9(7):e102323.

PMID: 25050994 PMC: 4106822. DOI: 10.1371/journal.pone.0102323.

References

Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y . Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997; 95(8):2032-6. DOI: 10.1161/01.cir.95.8.2032. View

Tripathi G, Sankhwar S, Sharma R, Baburaj V, Agrawal S . Role of thrombotic risk factors in end-stage renal disease. Clin Appl Thromb Hemost. 2009; 16(2):132-40. DOI: 10.1177/1076029609335911. View

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

Brown S, Lincoln M, Groen P, Kolodner R . VistA--U.S. Department of Veterans Affairs national-scale HIS. Int J Med Inform. 2003; 69(2-3):135-56. DOI: 10.1016/s1386-5056(02)00131-4. View

van der Put N, Gabreels F, STEVENS E, Smeitink J, Trijbels F, Eskes T . A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998; 62(5):1044-51. PMC: 1377082. DOI: 10.1086/301825. View

Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M . Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol. 2006; 17(10):2900-9. DOI: 10.1681/ASN.2005101106. View

Wright Jr J, Bakris G, Greene T, Agodoa L, Appel L, Charleston J . Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288(19):2421-31. DOI: 10.1001/jama.288.19.2421. View

Kolling K, Ndrepepa G, Koch W, Braun S, Mehilli J, Schomig A . Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol. 2004; 93(10):1201-6. DOI: 10.1016/j.amjcard.2004.02.009. View

Jamison R, Hartigan P, Kaufman J, Goldfarb D, Warren S, Guarino P . Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007; 298(10):1163-70. DOI: 10.1001/jama.298.10.1163. View

10.

Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M . Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. Am J Kidney Dis. 2007; 50(1):78-89, 89.e1. DOI: 10.1053/j.ajkd.2007.03.004. View

11.

den Heijer M, Lewington S, Clarke R . Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3(2):292-9. DOI: 10.1111/j.1538-7836.2005.01141.x. View

12.

Wolfinger R . An example of using mixed models and PROC MIXED for longitudinal data. J Biopharm Stat. 1997; 7(4):481-500. DOI: 10.1080/10543409708835203. View

13.

Genovese G, Friedman D, Ross M, Lecordier L, Uzureau P, Freedman B . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5. PMC: 2980843. DOI: 10.1126/science.1193032. View

14.

Koupepidou P, Deltas C, Christofides T, Athanasiou Y, Zouvani I, Pierides A . The MTHFR 677TT and 677CT/1298AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol. 2005; 24(3):287-94. View

15.

Ibrahim S, El Dessokiy O . Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis. Clin Exp Nephrol. 2009; 13(5):501-507. DOI: 10.1007/s10157-009-0194-2. View

16.

. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288(16):2015-22. DOI: 10.1001/jama.288.16.2015. View

17.

Rozen R . Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis. 1996; 19(5):589-94. DOI: 10.1007/BF01799831. View

18.

Pereira P, Stanton V, Jothy S, Tomlinson I, Foulkes W, Rozen R . Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. Oncol Rep. 1999; 6(3):597-9. DOI: 10.3892/or.6.3.597. View

19.

Agodoa L, Appel L, Bakris G, Beck G, BOURGOIGNIE J, Briggs J . Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285(21):2719-28. DOI: 10.1001/jama.285.21.2719. View

20.

Hill W . Estimation of linkage disequilibrium in randomly mating populations. Heredity (Edinb). 1974; 33(2):229-39. DOI: 10.1038/hdy.1974.89. View